Stéphane Bancel, Moderna CEO (Christopher Goodney/Bloomberg via Getty Images)

Mod­er­na looks past post-Covid 'low point' at a fu­ture based on com­bi­na­tion vac­cines, can­cer in­di­ca­tions

The Covid boom is over at Mod­er­na.

On Thurs­day, the biotech said it was brac­ing for sales to “hit a low point” in 2024 as de­mand wanes for the vac­cine that made it one of the in­dus­try’s biggest suc­cess sto­ries.

While Mod­er­na is stick­ing to its full-year 2023 sales guid­ance of $6 bil­lion to $8 bil­lion, it’s now say­ing that the low end is more re­al­is­tic and sales will be “at least $6 bil­lion.” Rev­enue next year will be around $4 bil­lion, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.